Targeting proteins to fight acute myeloid leukaemia
Understanding how proteins act inside acute myeloid leukaemia cells, to find new drug targets.
We have been funding expert research since 2016, aiming to ensure that every child and young person has a safe and effective treatment for their cancer, and that they can live long and happy lives post-treatment.
Understanding how proteins act inside acute myeloid leukaemia cells, to find new drug targets.
Developing a living systematic review of studies into new treatments for relapsed and refractory rhabdomyosarcoma.
Developing better models of rhabdomyosarcoma to test available treatments.
Developing more effective treatments for patients who have a low chance of survival, while reducing treatment and side effects for other patients.
Our proposal will deliver novel, less toxic targeted therapies with the potential to advance current treatment regimens for B-ALL. This will improve current outcomes, reduce side-effects in B-ALL patients and ultimately lead to a better quality of life for patients and their families.
Immunotherapy could be a potential treatment for ependymoma. To make immunotherapy effective we need to know more about how ependymoma works.
Ewing sarcoma is the second most common bone tumour in young people. The primary goal of this project is to fast-track a targeted drug combination for evaluation in clinical trials, with the aim of improving outcomes and minimising treatment associated morbidities for Ewing sarcoma patients.
Investigating a new method to improve the success of bone marrow transplants, using a different type of blood cells.
This research focuses on the development of novel drugs for the treatment of childhood brain tumours.